Myriad Genetics Licenses Chemotherapy Management Technology from Saladax | GenomeWeb
NEW YORK (GenomeWeb News) – Myriad Genetics said today it has licensed pharmacokinetic analysis technology from Saladax Biomedical for use in chemotherapy drug management.
 
Under the agreement, Myriad has gained an exclusive North American license for Saladax technology that allows doctors to personalize chemotherapy doses to improve the efficacy of the treatment and to minimize toxicity, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.